Aclarion enrolls first patient in CLARITY trial for spine surgery using Nociscan

From Nasdaq: 2025-06-25 16:58:00

Aclarion, Inc. (ACON) has enrolled the first patient in its CLARITY trial to evaluate the Nociscan platform in spine surgeries at the Texas Back Institute. Dr. Alexander Satin, principal investigator, is optimistic about correlating Nociscan’s biomarker data with surgical outcomes in patients with chronic low back pain. The study involves 300 patients randomized into two groups to assess pain reduction on the VAS scale at 12 months post-surgery. With 266 million people globally affected by degenerative spine disease, Nociscan aims to improve surgical decisions and patient outcomes. ACON closed at $7.08 on NasdaqCM, up 4.16% on Wednesday.



Read more at Nasdaq: Aclarion Enrolls First Patient In CLARITY Trial Evaluating Nociscan In Spine Surgery